[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2023000666A1 - Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl) -1h-pyrazole-4-carboxamide - Google Patents

Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl) -1h-pyrazole-4-carboxamide

Info

Publication number
CL2023000666A1
CL2023000666A1 CL2023000666A CL2023000666A CL2023000666A1 CL 2023000666 A1 CL2023000666 A1 CL 2023000666A1 CL 2023000666 A CL2023000666 A CL 2023000666A CL 2023000666 A CL2023000666 A CL 2023000666A CL 2023000666 A1 CL2023000666 A1 CL 2023000666A1
Authority
CL
Chile
Prior art keywords
methoxybenzamido
trifluoropropan
carboxamide
pyrazole
intermediates
Prior art date
Application number
CL2023000666A
Other languages
Spanish (es)
Inventor
Scott Alan Frank
Roger Ryan Rothhaar
Delgado Alonso Jose Arguelles
Charles Todd Eary
Jared Wade Fennell
Nicholas Andrew Magnus
Elizabeth Ann Mcfaddin
Stacey Renee Spencer
Radhe Krishan Vaid
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of CL2023000666A1 publication Critical patent/CL2023000666A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/30—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención proporciona procesos e intermedios clave para la sín-tesis de (S)-5-amino-3-(4-((5-fluoro-2-metoxibenzamido)metil)fenil)-1-(1,1,1-trifluoropropan-2-il)-1H-pirazol-4-carboxamida.The present invention provides key processes and intermediates for the synthesis of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1 -trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide.

CL2023000666A 2020-09-10 2023-03-08 Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl) -1h-pyrazole-4-carboxamide CL2023000666A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063076577P 2020-09-10 2020-09-10

Publications (1)

Publication Number Publication Date
CL2023000666A1 true CL2023000666A1 (en) 2023-08-18

Family

ID=78080458

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000666A CL2023000666A1 (en) 2020-09-10 2023-03-08 Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl) -1h-pyrazole-4-carboxamide

Country Status (17)

Country Link
US (1) US20230322682A1 (en)
EP (1) EP4211117A1 (en)
JP (1) JP7547622B2 (en)
KR (1) KR20230065307A (en)
CN (1) CN116323553A (en)
AR (1) AR123427A1 (en)
AU (2) AU2021342132B2 (en)
BR (1) BR112023002873A2 (en)
CA (1) CA3189884A1 (en)
CL (1) CL2023000666A1 (en)
CO (1) CO2023002865A2 (en)
EC (1) ECSP23017104A (en)
IL (1) IL301103A (en)
MX (1) MX2023002890A (en)
PE (1) PE20231013A1 (en)
TW (2) TW202317099A (en)
WO (1) WO2022056100A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019314302A1 (en) 2018-07-31 2021-01-28 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1H-pyrazole-4-carboxamide
WO2024176164A1 (en) 2023-02-22 2024-08-29 Assia Chemical Industries Ltd. Solid state form of pirtobrutinib
WO2024179558A1 (en) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Crystal form of pirtobrutinib, preparation method therefor and use thereof
WO2024194890A1 (en) * 2023-03-20 2024-09-26 Dr. Reddy’S Laboratories Limited Solid state forms of pirtobrutinib and process for the preparation of intermediate thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888960C (en) * 2012-11-02 2017-08-15 Pfizer Inc. Bruton's tyrosine kinase inhibitors
MA55064A (en) * 2015-12-16 2021-09-29 Loxo Oncology Inc COMPOUNDS USED AS KINASE INHIBITORS
EP3459940B8 (en) * 2016-05-16 2022-08-24 Evopoint Biosciences Co., Ltd. 5-aminopyrazole carboxamide derivative as btk inhibitor and preparation method and pharmaceutical composition thereof
CN108727230B (en) * 2017-04-21 2021-03-23 江苏希迪制药有限公司 Ibrutinib intermediate and preparation method thereof
CN107652294A (en) * 2017-11-14 2018-02-02 安徽诺全药业有限公司 A kind of preparation method of Ibrutinib
AU2019314302A1 (en) * 2018-07-31 2021-01-28 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1H-pyrazole-4-carboxamide
WO2022169798A2 (en) * 2021-02-03 2022-08-11 Accutar Biotechnology, Inc. Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders

Also Published As

Publication number Publication date
ECSP23017104A (en) 2023-04-28
TWI809489B (en) 2023-07-21
MX2023002890A (en) 2023-04-04
JP7547622B2 (en) 2024-09-09
WO2022056100A1 (en) 2022-03-17
CO2023002865A2 (en) 2023-03-27
TW202225146A (en) 2022-07-01
KR20230065307A (en) 2023-05-11
JP2023540802A (en) 2023-09-26
US20230322682A1 (en) 2023-10-12
AU2021342132B2 (en) 2024-05-23
AU2024202587A1 (en) 2024-05-09
CN116323553A (en) 2023-06-23
PE20231013A1 (en) 2023-07-05
AU2021342132A1 (en) 2023-04-13
EP4211117A1 (en) 2023-07-19
TW202317099A (en) 2023-05-01
CA3189884A1 (en) 2022-03-17
BR112023002873A2 (en) 2023-03-21
AR123427A1 (en) 2022-11-30
IL301103A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
CL2023000666A1 (en) Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl) -1h-pyrazole-4-carboxamide
CO2021003900A2 (en) Bispecific antigen-binding molecules comprising anti-fap clone 212
MX2022000504A (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro -1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide.
CO2020009901A2 (en) Novel crystalline forms
MD3864003T2 (en) Prodrug modulators of the integrated stress pathway
CY1123893T1 (en) PYRROLE AMIDES AS INHIBITORS OF ALPHA V INTEGRINS
MA45130B1 (en) Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-((4-[2-oxopyridin-1-yl)methyl]phenyl)methyl)pyrazole- 4-carboxamide as kallikrein inhibitors
HK1092152A1 (en) Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl] ureas and intermediates thereof
CY1125017T1 (en) HETEROCYLAMINO-SUBSTITUTED TRIAZOLES AS REGULATORS OF RHO-RELATED PROTEIN KINASE
CY1123105T1 (en) METHOD FOR THE PREPARATION OF ANDROGEN RECEPTOR COMPETITORS AND INTERMEDIATES THEREOF
MX2022000708A (en) Cardiac sarcomere inhibitor oral formulations.
BR112021020508A2 (en) 7h-pyrrolo[2,3-d]pyrimidine jak inhibitor
EA202192320A1 (en) CRYSTALLINE FORM OF 1- (1-OXO-1,2-DIHYDROISOCHINOLIN-5-YL) -5- (TRIFLUOROMETHYL) -N- [2- (TRIFLUOROMETHYL) PYRIDIN-4-YL] -1H-PYRAZOL-4-CARBOXAMIDE MONOHYDRATE
CL2022000089A1 (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide.
EA202190663A1 (en) CRYSTALLINE FORMS OF PHARNESOID X-RECEPTOR AGONIST
CO2021005141A2 (en) Solid crystalline forms of n- (1 - ((2- (dimethylamino) ethyl) amino) -2-methyl-1-oxopropane-2-yl) -4- (4- (2-methyl-5 - ((2s, 3r, 4r, 5s, 6r) -3,4,5-trihydroxy-6- (methylthio) tetrahydro-2h-pyrano-2-yl) benzyl) phenyl) butanamide and methods for its synthesis
CL2024000248A1 (en) Compositions and methods for anti-pacap antibodies
CO2022001513A2 (en) Process and intermediates for the preparation of pyroxasulfone
CY1124940T1 (en) DIMETHYLAMINOETHANOL SALT OF A GLP-1 RECEPTOR REGULATOR
CY1124177T1 (en) COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T
NO20051867L (en) Process for preparing intermediates
DK1631291T3 (en) Use of tyrosine kinase inhibitors to treat diabetes
MX2024010029A (en) The preparation of n-(1-methylcyclopropyl)-2-(3-pyridinyl)-2h-ind azole-4-carboxamide and intermediates thereof.
MX2017016042A (en) Polymorphs of a pges-1 inhibiting triazolone compound.
EA202190511A1 (en) CRYSTALLINE (R) -5-CARBAMOILPIRIDIN-3-IL-2-METHYL-4- (3- (TRIFLUOROMETOXY) BENZYL) PIPERAZIN-1-CARBOXYLATE, ITS COMPOSITIONS AND METHODS OF APPLICATION